Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.
The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. In parallel, Crinetics is advancing CRN04894, a vasopressin V2 receptor antagonist for the management of hyponatremia, and CRN04912, an oral ghrelin receptor inverse agonist being developed for congenital hyperinsulinism. These programs reflect Crinetics’ strategy to build a focused pipeline addressing multiple rare endocrine disorders with high unmet medical need.
Founded in 2013 and headquartered in San Diego, California, Crinetics Pharmaceuticals operates with an organizational structure designed to support both in-house discovery and external collaborations. The company engages with academic research centers and clinical investigators across North America and Europe to advance its clinical studies and to explore additional indications for its pipeline candidates. Crinetics’ integrated approach combines medicinal chemistry, translational biology and clinical development expertise under one roof, with the goal of accelerating the path from laboratory to patient care.
As a publicly traded company on the NASDAQ under the ticker CRNX, Crinetics maintains a governance framework led by a board of directors and an executive leadership team with deep experience in endocrinology, drug development and regulatory affairs. The company continues to invest in expanding its pipeline and strengthening its scientific capabilities to bring new treatment options to patients with rare hormonal disorders.
AI Generated. May Contain Errors.
